Fig. 2From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsForest plot showing progression-free survival in PARP inhibitor arm (case) and chemotherapy/placebo arm in platinum-sensitive ovarian cancer (control)Back to article page